

Institut für Innovation & Evaluation im Gesundheitswesen

Office:

Rathausplatz 12-14 D-65760 Eschborn Tel: +49 (6196) 7766-410 Fax: +49 (6196) 7766-416 info@innoval-hc.com www.innoval-hc.com

HEALTH ECONOMICS SUMMER SCHOOL

A program offered by INNOVAL^{HC} in cooperation with the University of Heidelberg - Mannheim Institute of Public Health (MIPH)

Heidelberg

September 29th – October 2nd, 2008

Scientific Program

V6 - As at September 09, 2008

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 2/12



Program Overview

CoreEconomic Evaluation of Health Care Programs:ProgramCurrent Concepts, Controversies,
and International Experience

September 29 – October 02, 2008

Advanced topics and international practices related to the use of economic evaluation to inform health care policy:

- \neg Economic theory
- ¬ Willingness-to-pay
- \neg Preferences and utility
- ¬ Health-adjusted life years (HALYs, including QALYs)
- \neg Quantifying quality of life
- \neg Expected utility theory
- \neg Utility measurement
- Biomedical ethics and health economic evaluations

International overview:

Health technology assessments (HTAs) including economic evaluation:

- \neg Australia (PBAC)
- ¬ Canada (CADTH)
- ¬ England and Wales (NICE)
- ¬ Sweden (LFN)
- \neg USA (managed care)
- \neg France (HAS)
- Pharmaceutical Price Regulation Scheme (PPRS) and "value-based pricing" in the UK
- \neg Stakeholder perspectives

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 3/12



Faculty

Friedrich Breyer (Konstanz, Germany) John F.P. Bridges (Baltimore, Maryland) Martin J. Buxton (London, England) J. Jaime Caro (Montréal, Québec) Gérard de Pouvourville (Paris, France) Sören Holm (Cardiff, Wales) Panos G. Kanavos (London, England) Peter J. Neumann (Boston, Massachussetts) Erik Nord (Oslo, Norway) Ulf Persson (Lund, Sweden) Jeff Richardson (Melbourne, Victoria) Michael Schlander (Heidelberg and Ludwigshafen, Germany)* Darcey Terris (Heidelberg, Germany) Koen Torfs (Neuss, Germany)

*Scientific Program Director

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 4/12



Faculty

Friedrich Breyer

Chair of Economic and Social Policy, University of Konstanz (Germany), Economics Department.

Member of the executive board and chairman, health economics committee of the association of German-speaking economists (*Verein für Socialpolitik*); member of the advisory board of the Federal Ministry of Economics and Technology (Germany); Research Professor at the German Institute of Economic Research in Berlin; author of a major health economics textbook.

John F.P. Bridges

Assistant Professor at the Johns Hopkins Bloomberg School of Public Health, Baltimore (Maryland)

As an economist by training, John is conducting research at the intersection of health economics, pharmacoeconomics and outcomes research, and health services research; major areas of scientific interest include the application of patient-centered methods; Research Economist at the National Bureau of Economic Research (NBER); New York, NY.

Martin J. Buxton

Professor and Director of the Health Economics Research Group (HERG) at Brunel University, London.

Over 20 years experience in the methods and practice of economic evaluation in health care; previously member of the Appraisal Committee of the National Institute for Clinical Excellence (NICE); member of the Reference Group established by NICE to review the new Single Technology Appraisal (STA) process.

J. Jaime Caro

Adjunct Professor of Medicine and of Epidemiology & Biostatistics at McGill University, Montréal, Canada; Scientific Director of Caro Research (now part of UBC), Montréal, QC, and Boston, MA.

Chairman of the international health economic advisory board of the German Institute for Quality and Efficiency in Health Care (IQWiG); main research interests in the field of health technology assessment, in particular in the design of economic models and related analytic techniques

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 5/12



Gérard de Pouvourville

Professor of Health Economics and Department Chair / Senior Research Director at ESSEC, Business School Paris – Singapore, Paris, France.

Chairman of the French Health Economists Association, Vice Chairman of the National Observatory for Drug Prescription and Use, member of the board of INSERM, the French National Health Research Institute; major fields of research include health technology assessments including economic evaluation.

Sören Holm

Professorial Fellow in Bioethics at Cardiff Law School, Cardiff University, Wales.

Professor of Medical Ethics at the University of Oslo, Norway; editor-in-chief of *The Journal of Medical Ethics*; member of the Danish Council of Ethics from 1994 to 1999; currently President of the European Society for the Philosophy of Medicine and Health Care.

Panos G. Kanavos

Senior Lecturer in International Health Policy and Merck Fellow in Pharmaceutical Economics at the London School of Economics (LSE) and Professor at the University of Lausanne, Switzerland.

Panos Kanavos has acted as advisor to the World Bank, the World Health Organization, the European Commission, the Organisation for Economic Cooperation and Development (OECD), the American Association for Retired Persons and Ministries of Health as well as other governmental and non-governmental organizations in over 21 transition and developing countries.

Peter J. Neumann

Professor of Medicine and Director of the Center for the Evaluation of Value and Risk in Health at Tufts University / New England Medical Center, Boston (Massachussetts).

Past President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and trustee of the Society for Medical Decision Making; directing a project to develop a comprehensive registry of cost-effectiveness analyses in health care.

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 6/12



Erik Nord

Senior Researcher at the Norwegian Institute of Public Health, Oslo (Norway), since 2003 in the Department of Mental Health.

Assignments for the OECD, the WHO, and the Norwegian National Council for Priority Setting in Health Care; long-standing research interests in methods and procedures for economic evaluation and priority setting; author of a textbook on "cost-value analysis" in health care.

Ulf Persson

Chairman, Swedish Institute for Health Economics (IHE), Lund (Sweden).

Over 20 years research experience in the development and application of economic evaluation methods in health care, with particular regard to the introduction and utilization of medical technologies.

Jeff Richardson

Professor, Faculty of Economics at Monash University (Melbourne / Clayton, Victoria); Foundation Director of the Centre for Health Economics (CHE).

President of the Australian Health Economists' Group from 1984 to 1991; member of the Pharmaceutical Remuneration Tribunal in Australia; member of the editorial boards of five leading health economic journals.

Michael Schlander

Founding Chairman of the Institute for Innovation & Valuation in Health Care (INNOVAL^{HC}); Professor of Health Care Management at the University of Applied Economic Sciences Ludwigshafen (Germany).

Health Economist at the *Mannheim Institute of Public Health, Social and Preventive Medicine* (University of Heidelberg); over 15 years experience in executive management roles (in clinical research and marketing & as CEO) in the international pharmaceutical industry.

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 7/12

Darcey Terris

Postdoctoral Fellow at the Mannheim Institute for Public Health, Social and Preventive Medicine at the University of Heidelberg (Germany).

Main research interests include quality management in health care and preference-based measures of health benefits.

Koen Torfs

Vice President, Health Economics & Public Affairs, Janssen-Cilag GmbH (Neuss, Germany). Over 20 years experience in the economic evaluation of health care interventions.

Rosalie Viney

Associate Professor and Deputy Director at the Centre for Health Economics Research & Evaluation, University of Technology, Sydney, New South Wales. Chair of the Australian Pharmaceutical Benefits Advisory Committee (PBAC)'s Economics Sub-Committee; research areas include utilization of health services, valuation of health outcomes, the use of economic evaluation in resource allocation, and measurement of individual's preferences for health care services.



Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 8/12



Schedule

Core Economic Evaluation of Health Care Programs

¹¹ 1. Current Concepts

Controversies
International Experience

September 29 – October 02, 2008

Monday (Sept. 29)

From 10:00 am to 7:30 pm

Current Concepts

Economic Evaluation of Health Care Programs: A Typology *Michael Schlander*

Valuation of Outcomes: Willingness-to-Pay and Health-Adjusted Life Years *Michael Schlander*

Preferences as a Latent Construct *Darcey Terris*

The Concept of Utility and the Role of von Neumann-Morgenstern Expected Utility Theory (EUT) *Jeff Richardson*

Quantifying "Quality of Life" (Exercise) Michael Schlander

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 9/12



Tuesday (Sept. 30)

From 9:00 am to 9:00 pm

Current Concepts and Controversies

Insights from Exercise *Michael Schlander*

Economic Welfare Theory & Cost-Benefit Analysis *Friedrich Breyer*

Measuring Social Preferences for Priority-Setting *Erik Nord*

Extrawelfarism: "The Logic of Cost-Effectiveness" *Martin J. Buxton*

Lunch

Outline of a Fairness-Based Evaluation Framework *Jeff Richardson*

Priority-Setting in Health Care: Focus on Fair Process? *Sören Holm*

Discussion with the Experts Friedrich Breyer, Martin J. Buxton, Sören Holm, Erik Nord, Jeff Richardson, Michael Schlander, et al.

Supper

International Experience I

Overview: Health Technology Assessments (HTAs) in Europe *Panos G. Kanavos*

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 10/12



Wednesday (Oct. 01)

From 9:00 am to 9:00 pm

International Experience II

NICE and the NHS *Martin J. Buxton*

Recent Developments in England, including "Value-Based Pricing" *Martin J. Buxton*

North America: CEA in Canada and the United States *Peter J. Neumann*

Lunch

International Experience III

CEA and CUA: Common Methodological Flaws *Peter J. Neumann*

Australia: The Pharmaceutical Benefits Scheme (PBS) *Jeff Richardson / Rosalie Viney*

Measuring Patient Preferences *John F.P. Bridges*

Supper

International Experience IV

Sweden: The Pharmaceutical Benefits Board (LFN) *Ulf Persson*

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 11/12



Thursday (Oct. 02)

From 9:00 am to 3:30 pm

International Experience V

Advanced Modeling Techniques: Appropriate Use and International Acceptance J. Jaime Caro

HAS: Economic Evaluation in France and its Political Context *Gérard de Pouvourville*

IQWiG: Economic Evaluation in Germany *J. Jaime Caro*

A Stakeholder Perspective

From the International Pharmaceutical Industry *Koen Torfs*

Discussion and Conclusions

Discussion with the Experts: Which Way Forward? John F.P. Bridges, J. Jaime Caro, Ulf Persson, Gérard de Pouvourville, Michael Schlander, Koen Torfs, et al.

Heidelberg (September 29 – October 2, 2008) Program Overview (As at Sept. 09, 2008) – Page 12/12





Villa Bosch in Heidelberg

Venue: Studio of Villa Bosch, Heidelberg / Germany Website: http://academy.innoval-hc.com Details: For further information, please contact Sigrid Steinebach at the Institute: Mail Sigrid.Steinebach@innoval-hc.com Phone +49-6196-7766-410 Facsimile +49-6196-7766-416

Please note that situations might arise in the future that require change and revision of the program. Program as at September 09, 2008.